Polypharmacy & deprescribing (medication review; STOPP/START, anticholinergic burden)
Medication safety · Geriatric & General
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Polypharmacy (commonly >=5 regular medicines) is problematic when the harms outweigh benefit: adverse drug reactions, drug-drug and drug-disease interactions, falls, delirium, bleeding, AKI, hospital admission and poor adherence. Deprescribing is the planned, supervised, patient-centred process of reducing or stopping drugs that are no longer of benefit or may be causing harm. It is a core geriatric intervention and should be considered at every admission, discharge and medication review.
Red flags
- Recent fall, delirium, bleeding or AKI temporally linked to a drug
- Hypoglycaemia on sulfonylurea/insulin in a frail patient
- Serotonin syndrome / anticholinergic toxidrome from combined agents
- Bradycardia/hypotension from accumulating cardiac drugs in renal impairment
- Withdrawal syndromes from abrupt cessation (seizures from benzodiazepine withdrawal, adrenal crisis from steroid withdrawal)
Assessment
Differential diagnosis
- Adverse drug reaction mimicking new disease (prescribing cascade — e.g. amlodipine oedema treated with a diuretic)
- Drug-induced falls/delirium/confusion
- Drug-induced AKI (triple whammy: ACEi/ARB + diuretic + NSAID)
- Anticholinergic toxicity (dry mouth, constipation, retention, cognitive impairment)
- Non-adherence due to pill burden
Investigations
- Full reconciled medication list (include OTC, herbal, inhalers, eye drops, topical, as-required)
- U&E/eGFR (dose adjustment, nephrotoxic combinations), LFTs, FBC
- Calculate anticholinergic burden (ACB score); identify high-risk drugs
- Apply explicit tools: STOPP/START criteria, Beers criteria, NO TEARS, drug-burden index
- Check indication, ongoing benefit and intended duration for EACH drug
- Postural BP, HbA1c, INR/anticoagulation review as relevant
Management
- Reconcile the full list and establish what the patient actually takes and their priorities/goals
- For each drug ask: is there a current valid indication? Is it still achieving benefit? Do harms/risks outweigh benefit given life expectancy and goals? Is the dose appropriate for renal/hepatic function?
- Identify drugs to target first: those causing harm now, no indication, duplicates, high anticholinergic burden, drugs with no benefit given limited prognosis, and unresolved prescribing cascades
- Prioritise with the patient; stop one or a few at a time where possible to allow monitoring
- Taper drugs that need it (benzodiazepines, Z-drugs, opioids, gabapentinoids, SSRIs/SNRIs, beta-blockers, PPIs, corticosteroids, antipsychotics) to avoid withdrawal/rebound
- Document rationale, plan and monitoring; communicate clearly to patient, carer and GP
- Arrange follow-up to review symptoms, withdrawal effects and whether a drug needs restarting
- Use START criteria to also identify under-prescribing (e.g. missing bone protection, anticoagulation in AF, statin where indicated)
Drugs & doses
Common deprescribing targets (older/frail): benzodiazepines & Z-drugs (falls, cognition), 'z' and long-acting sulfonylureas (hypoglycaemia), NSAIDs (GI/renal/CV), long-term PPIs without indication, anticholinergics (oxybutynin, amitriptyline, promethazine), antipsychotics in dementia, long-term opioids/gabapentinoids [verify local]
Taper examples: benzodiazepine reduce by ~1/8 of dose every 1-2 weeks; long-term oral prednisolone wean per HPA-axis risk; PPI step down then alternate-day then stop [verify local dose]
Avoid the 'triple whammy': ACE inhibitor/ARB + diuretic + NSAID (AKI risk) — stop the NSAID
Beware prescribing cascades: calcium-channel-blocker oedema, metoclopramide/antipsychotic parkinsonism, PPI-induced hypomagnesaemia
Disposition
Outpatient/structured medication review (GP, pharmacist) or inpatient at admission/discharge. Ensure clear communication of changes and monitoring plan to primary care; safety-net for withdrawal effects.
Complications & pitfalls
- Adverse drug withdrawal events / rebound (hypertension, reflux, insomnia, anxiety, pain)
- Return of the treated condition if stopped inappropriately
- Adrenal crisis if long-term steroids stopped abruptly
- Patient/carer anxiety and loss of confidence if not well communicated
Exam pearls
- Tools: STOPP/START v3, Beers criteria, anticholinergic burden (ACB) scale, NICE multimorbidity guidance (NG56).
- Deprescribing is not 'doing nothing' — it is active, monitored care with follow-up.
- Match treatment intensity to life expectancy and goals: statins, tight glycaemic/BP targets and bisphosphonates may offer little benefit in limited prognosis.
- Always taper the 'A-B-C-D-G-O' drugs (antidepressants, benzodiazepines, corticosteroids, dopaminergics, gabapentinoids, opioids) and PPIs/beta-blockers.
- Every prescribing cascade is an opportunity to deprescribe the original culprit.
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.